NEW DELHI - Indian generic giant Ranbaxy said Wednesday it has spent over $300 million to overhaul its operations and ensure no repeat of drug safety violations that led to a multimillion-dollar U.S. fine.
Last week, New Delhi-based Ranbaxy pleaded guilty in the United States to charges of making and distributing adulterated drugs made at its two Indian plants of Paonta Sahib and Dewas, agreeing to a $500 million settlement....
More